Sponsors

Lead Sponsor

University of Chicago

Collaborators

University of British Columbia

This study's specific objectives include: 1. Evaluating pharmacokinetic (concentration-time) and pharmacodynamic (concentration- effect) parameters for dalteparin and UFH prior to pregnancy, during the 1st, 2nd and 3rd trimesters and postpartum, using revised dosing protocols based on previous study. 2. Determining therapeutic response to the heparins, i.e. live birth rate and lack of maternal or fetal complications, in relation to drug exposure, based on AUC. 3. Documenting maternal and fetal complications during pregnancy for dalteparin and UFH, using the revised dosing protocols.

Related studies

RECRUITINGNA

Cardiac Autonomic and Anxiety Regulation Via Closed-loop nEurofeedback in Recurrent Pregnancy Loss

NCT07325370 · Recurrent Pregnancy Loss, Anxiety

RECRUITINGNA

High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss and Anxiety

NCT06968026 · Recurrent Pregnancy Loss, Anxiety Disorders

RECRUITING

Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Cardiac Autonomic and Anxiety Regulation Via Closed-loop nEurofeedback in Recurrent Pregnancy Loss

High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss and Anxiety

The Combined First Trimester Screening

Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History

Genomics and Microbiome Investigation in Cases of Recurrent Pregnancy Losses

Trial snapshot

Condition

Locations shown

For caregivers